Validation and clinical application of an LC-MS/MS method for the quantification of everolimus using volumetric absorptive microsampling

Autor: Verheijen, R B, Thijssen, B, Atrafi, F, Schellens, J H M, Rosing, H, de Vries, N, Beijnen, J H, Mathijssen, R H J, Steeghs, N, Huitema, A D R, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Přispěvatelé: Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Medical Oncology
Jazyk: angličtina
Rok vydání: 2019
Předmět:
Zdroj: Journal of Chromatography B. Analytical Technologies in the Biomedical and Life Sciences, 1104, 234-239. Elsevier
Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 1104, 234. Elsevier
Journal of Chromatography B, 1104, 234. Elsevier
ISSN: 1873-376X
1570-0232
Popis: Everolimus is a mammalian target of rapamycin inhibitor approved for the treatment of various tumor types. Less invasive measurement of everolimus concentrations could facilitate pharmacokinetic studies and personalized dosing based on whole blood concentrations, known as therapeutic drug monitoring. Volumetric Absorptive Microsampling (VAMS) has been introduced as a patient friendly, less invasive sampling technique to obtain an accurate volume of whole blood regardless of hematocrit value. We describe the bioanalytical validation and clinical application of a liquid chromatography tandem mass spectrometry (LC-MS/MS) method to quantify everolimus using VAMS. For the quantification, 13C2D4-Everolimus was used as internal standard (IS). Everolimus and the IS were extracted with methanol from the VAMS device, which was evaporated after ultrasonification and shaking. The residue was reconstituted in 20 mM ammonium formate buffer and methanol (50%, v/v) of which 5 μL was injected into the LC-MS/MS system. Quantification was performed for the ammonium adduct of everolimus in positive electrospray ion mode. The VAMS method met all pre-defined validation criteria. Accuracy and precision were within 11.1% and ≤14.6%, respectively. Samples were shown to be stable on the VAMS device for at least 362 days at ambient temperatures. Considerable biases from −20 to 31% were observed over a 30–50% hematocrit range. Although the method fulfilled all validation criteria, the perceived advantage of VAMS over dried blood spot sampling could not be demonstrated. Despite the effect of hematocrit, using an empirically derived formula the whole blood everolimus concentration could be back calculated with reasonable accuracy in the clinical application study.
Databáze: OpenAIRE
Externí odkaz: